- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03928938
Follow-up of Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy by Electronic Patient Reported Outcomes-tool
Electronic patient reported outcome (ePRO) tools have improved survival and quality of life (QoL) of cancer patients receiving chemotherapy, and in the follow-up of lung cancer patients. Current study investigates electronic patient reported outcome tool in the follow-up of cancer patients receiving immune checkpoint inhibitor therapy.
Current study aims to evaluate 1) patient reported symptoms and their severity, 2) Number of triggered alerts by the tool and their correlation to treatment side-effects, cancer progression, other medical events or survival, 3) Correlation between different symptoms and the correlation of symptoms to treatment side-effects, cancer progression, other medical events or survival,4) QoL of patients and correlation of changes in QoL to treatment side-effects, cancer progression, other medical events or survival, 5) Patient compliance, 6) Correlation of baseline laboratory values to treatment side-effects, cancer progression, other medical events or survival.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jussi P Koivunen, M.D., Ph.D
- Phone Number: +35883153789
- Email: jussi.koivunen@ppshp.fi
Study Contact Backup
- Name: Sanna Iivanainen, M.D.
- Phone Number: +35883153038
- Email: sanna.iivanainen@ppshp.fi
Study Locations
-
-
-
Helsinki, Finland, 00180
- Recruiting
- Docarates Cancer Center
-
Contact:
- Tuomo Alanko, M.D., Ph.D
-
Principal Investigator:
- Tuomo Alanko, M.D., Ph.D
-
Turku, Finland, 20521
- Recruiting
- Pia Vihinen
-
Contact:
- Pia Vihinen, MD, Ph.D
-
Principal Investigator:
- Pia Vihinen, MD, Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Advanced cancers
- Immune checkpoint inhibitor therapy initiated within +/- 2wks
- Age >18y
- ECOG 0-3
- Patient compliant with the study procedures
Exclusion Criteria:
- Immune checkpoint inhibitor therapy initiated > 2wks ago
- General vulnerability affecting the participation in the trial
- No internet access
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Electronic follow-up
Follow-up of cancer patients treated with immune checkpoint inhibitor therapy using electronic patient reported outcomes-tool
|
Electronic patient reported outcomes-tool
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the spectrum of patient reported symptoms
Time Frame: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Percentages of patient reported symptoms using KaikuHealth 17 symptom e-questionnaire.
Individual questions evaluate the presence of a specific symptom e.g.
nausea.
Questions are answered yes or no.
|
At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Change in Patient reported symptom severity
Time Frame: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Percentages of patient reported symptoms and their severity according NCI-CTCAE by KaikuHealth algorithm
|
At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Change in the number of triggered alerts by the tool
Time Frame: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Number of triggered alerts by the tool and their correlation to treatment side-effects, cancer progression, other medical events in percentages or survival.
|
At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Changes in Quality of Life according to QLQ-C30 Summary scores
Time Frame: At baseline, and at 4, 8, and 12weeks
|
The correlation of the Summary score of QLQ-C30 to treatment side-effects, cancer progression, or other medical events or survival. The Core Quality of life questionnaire (QLQ-C30) is a validated cancer health-related quality-of-life questionnaire that includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality of life and financial impact. Subjects respond on a four-point-scale from "not at all" to "very much" for most items. Raw scores are linearly converted to a 0-100 scale. For the functioning scales and global QoL higher scores indicate better functioning; for the symptom scales higher scores indicate higher symptom burden. The summary score of QLQ-C30 is calculated from the mean of 13 of 15 QLQ-C30 scales (the Global Quality of Life scale and the Financial Impact scale are not included). |
At baseline, and at 4, 8, and 12weeks
|
Correlation between changes in different symptoms and their severity to treatment side-effects, cancer progression, other medical events, or survival.
Time Frame: At 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation between different patient reported symptoms and their severity to treatment side-effects, cancer progression or other medical events in percentages or survival.
|
At 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Changes in Patient compliance Questionnaire
Time Frame: At 4, 8, and 12weeks
|
Patient compliance using KaikuHealth e-questionnaire addressing usability (easiness to use from scale: very easy to very difficult; need of assistance to use the program: yes/no; how understandable are questions in symptom questionnaire from scale: totally agree to totally disagree) and user experience (use of the ePRO tool will better your cancer care: yes-no, do not know; use of the ePRO tool has been useful: yes-no-do not know; would you recommend the ePRO tool for cancer care: yes-no-do not know).
Analysis is done on percentages of each answer choice at specific time point(s).
|
At 4, 8, and 12weeks
|
Changes in patient compliance according to answering rate to symptom questionnaires
Time Frame: At 4, 8, and 12weeks
|
Patient compliance using response rates (within one week) to symptom questionnaires in percentages from sent requests
|
At 4, 8, and 12weeks
|
Change in patient compliance according to answering rates to QLQ-C30 questionnaire
Time Frame: At 4, 8, and 12weeks
|
Patient compliance using response rates to QLQ-C30 questionnaires (within one week) in percentages from sent requests.
The QLQ-C30 questionnaire includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality of life and financial impact.
Subjects respond on a four-point-scale from "not at all" to "very much" for most items.
Raw scores are linearly converted to a 0-100 scale.
For the functioning scales and global QoL higher scores indicate better functioning; for the symptom scales higher scores indicate higher symptom burden.
The summary score of QLQ-C30 is calculated from the mean of 13 of 15 QLQ-C30 scales (the Global Quality of Life scale and the Financial Impact scale are not included).
|
At 4, 8, and 12weeks
|
Correlation of change in baseline Hb values compared to control Hb values to treatment side-effects, cancer progression, other medical events or survival.
Time Frame: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline Hb values compared to control Hb values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.
|
At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline leucocyte values compared to control leucocyte values to treatment side-effects, cancer progression, other medical events or survival.
Time Frame: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline leucocyte compared to control leucocyte values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.
|
At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline lymphocyte values compared to control lymphocyte values to treatment side-effects, cancer progression, other medical events or survival.
Time Frame: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline lymphocyte values compared to control lymphocyte values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.
|
At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline neutrophil values compared to control neutrophil values to treatment side-effects, cancer progression, other medical events or survival.
Time Frame: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline neutrophil values compared to control neutrophil values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.
|
At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline CRP values compared to control CRP values to treatment side-effects, cancer progression, other medical events or survival.
Time Frame: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Correlation of change in baseline CRP values compared to control CRP values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.
|
At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jussi P Koivunen, M.D., Ph.D, Oulu University Hospital
Publications and helpful links
General Publications
- Iivanainen S, Ekstrom J, Virtanen H, Kataja VV, Koivunen JP. Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. BMC Med Inform Decis Mak. 2021 Jun 30;21(1):205. doi: 10.1186/s12911-021-01564-0.
- Iivanainen S, Alanko T, Vihinen P, Konkola T, Ekstrom J, Virtanen H, Koivunen J. Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. JMIR Form Res. 2020 Oct 28;4(10):e17898. doi: 10.2196/17898.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 9/2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Palleon Pharmaceuticals, Inc.RecruitingMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
Clinical Trials on Electronic patient reported outcomes
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRecruitingBreast Cancer | Colorectal CancerCanada
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationRecruitingGynecologic Cancer | Ovarian Cancer | Endometrial Cancer | Gynecologic NeoplasmDenmark
-
UNC Lineberger Comprehensive Cancer CenterRecruitingBreast CancerUnited States
-
Stanford UniversityAstraZenecaCompletedCardiovascular Diseases | Vascular Diseases | Arteriosclerosis | Arterial Occlusive Diseases | Peripheral Arterial Disease | Peripheral Vascular Diseases | Atherosclerosis | Intermittent Claudication | Signs and Symptoms | Patient ComplianceUnited States
-
Herlev and Gentofte HospitalNot yet recruitingKidney Cancer | Urologic Neoplasms | Metastatic Renal Cell Carcinoma | Urologic Cancer | Advanced Renal Cell Carcinoma | Kidney NeoplasmDenmark
-
Zhejiang UniversityRecruiting
-
Manuela EicherRecruitingPatient Reported Outcome Measures | Patient SafetySwitzerland
-
University of California, San FranciscoNot yet recruitingGastrointestinal Cancers | Gastrointestinal Cancer MetastaticUnited States
-
University Women's Hospital TübingenNational Center for Tumor Diseases (NCT), University Hospital Heidelberg,... and other collaboratorsUnknownBreast Cancer MetastaticGermany